Previous close | 14.00 |
Open | 14.06 |
Bid | 13.76 x 700 |
Ask | 13.79 x 100 |
Day's range | 13.55 - 14.13 |
52-week range | 6.46 - 35.67 |
Volume | |
Avg. volume | 3,542,904 |
Market cap | 2.129B |
Beta (5Y monthly) | 2.32 |
PE ratio (TTM) | 153.17 |
EPS (TTM) | 0.09 |
Earnings date | 29 Apr 2024 - 03 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 30.43 |
NEW YORK, April 15, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentation of data from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the 2024 American Academy of Neurology (AAN) annual meeting, being held in Denver, Colorado. A link to the data presented yesterday is included below. Two additional presentations will be shared on Wednesday April 17, 2024. Michael
It is hard to get excited after looking at TG Therapeutics' (NASDAQ:TGTX) recent performance, when its stock has...
In this article, we’re going to take a look at 13 best biotech stocks to buy under $20. To see more stocks that made the list, you can skip ahead and jump straight to the top 5 best biotech stocks to buy under $20. When it comes to investing, few industries are as exciting to […]